Composition comprising at least one water-soluble pharmaceutically acceptable salt of elafibranor having improved intestinal absorption
US11185520B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 28, 2017 |
| Grant date | Nov 30, 2021 |
| Priority date | — |
| Expiry date | Sep 28, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P1/16
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A composition comprising, as an active principle, a pharmaceutically acceptable salt of elafibranor, characterised in that the pharmaceutically acceptable salt of elafibranor is chosen from at least a salt of choline, of ethanolamine, or of diethanolamine, or of L-lysine, or of piperazine, or of calcium, or of tromethamine. More particularly, one or more embodiments relate to the use of elafibranor salts with a view to improving stability and solubility compared with elafibranor in the basic form thereof. These salts make it possible to establish pharmaceutical formulations in various advantageous forms as intravenous injections or formulations by enteral route having quicker and less variable absorption and consequently better bioavailability.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.